drug_type
RELEVANT_DRUG
intervention_type
Biological (gene-modified cellular immunotherapy; CAR T cells)
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD19, enabling MHC-independent recognition and activation to proliferate, release cytotoxic effectors and cytokines, and deplete CD19+ malignant and normal B cells.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD19 on B cells. CAR engagement activates T cells independently of MHC, driving proliferation, cytokine release, and cytotoxic killing (perforin/granzymes) of CD19-positive malignant and normal B cells, leading to B-cell depletion.
drug_name
Anti-CD19 CAR T cells
nct_id_drug_ref
NCT04100187